LOS ALTOS, Calif., Nov. 19, 2015 /PRNewswire/ -- RenovoRx, a leading developer of innovative solutions for targeted delivery of therapeutics to selected sites in the peripheral vascular system, today announced that the company was selected by the Stanford-affiliated StartX MED program for its Fall 2015 session. StartX is an educational non-profit organization that accelerates the development of Stanford's top entrepreneurs through experiential education and collective intelligence. Specifically, StartX Med is a medical vertical of StartX focused on Stanford's top medical entrepreneurs.
"As a Stanford Alumna as well as StartX MED Mentor since the vertical was developed in 2012, I am thrilled to see RenovoRx join the StartX family," said Marta Gaia Zanchi, PhD, Lecturer at Stanford University's School of Medicine with the Biodesign Program, former Chief Executive Officer of RenovoRx until 2014 and now member of the Advisory Board of the company. "I am consistently impressed with the quality of the staff, companies and mentors at StartX. Companies in the program not only receive invaluable mentoring and support on many aspects of their business: they are provided access to Stanford's wide network of top-tier investors, corporate representatives and press. These mentoring, support and connections are invaluable to help a company establish a solid foundation for continuous success and value creation."
"The Stanford StartX application process is highly selective and heavily contested. We are honored to be one of the few companies selected: a testament to the success we have achieved thus far and the future potential of our business," said Shaun Bagai, Chief Executive Officer of RenovoRx. "Working with the StartX team will also allow RenovoRx to collaborate with other entrepreneurs, increase our breadth of resources, and contribute to the start-up community."
StartX is an educational non-profit that accelerates the development of Stanford's top entrepreneurs through experiential education and collective intelligence. As a partner of Stanford University and Stanford Health Care as well as many Stanford programs and the Stanford student government, StartX supports all Stanford founders, including undergraduates, Master's students, PhD students, postdocs, alumni and professors. Founders in the StartX community are carefully selected, and each session the organization welcomes founders who are amazingly diverse, passionate, and talented. They're also generous. As members of StartX's thriving and supportive community, they help each other approach obstacles from different perspectives. They have studied medicine, engineering, business, humanities, law, science, and more. This creation of an interdisciplinary environment contributes to the StartX community norm of trust and information sharing. StartX is supported through foundation grants and corporate partnerships and takes no equity in its companies.
RenovoRx (www.renovorx.com) is developing innovative solutions for the isolation of blood flow and delivery of fluids, including diagnostic material and therapeutic agents, to selected sites in the peripheral vascular system. The ability to deliver these materials at high concentration to specific vasculature, safely and without perfusion overlap to other regions, is a central paradigm of the company's technology. RenovoRx is an early stage startup based in Silicon Valley, California, and its top financial backers include Golden Seeds, Astia Angels, Sand Hill Angels, The Angels' Forum, The Halo Fund III, L.P., and Amidi, LLC.